Dispatch Bio

Dispatch Bio is a private, preclinical-stage biotech developing a universal treatment for solid tumors using its first-in-class Flare platform. The platform combines a tumor-specific virus with a novel universal antigen to precisely tag and clear cancer cells while overcoming the immunosuppressive tumor microenvironment. Backed by a seasoned leadership team with deep drug development experience and notable investors like ARCH Venture Partners, the company aims to address the significant unmet need in oncology, where solid tumors represent approximately 90% of all cancers.

The Flare platform is a first-in-class immunotherapy approach for solid tumors. It uses a tumor-specific oncolytic virus to deliver a novel universal synthetic antigen (Flare) that tags cancer cells. This tag then acts as a beacon to guide a coordinated immune system attack, overcoming challenges of target specificity and the immunosuppressive tumor microenvironment.

Dispatch Bio competes in the crowded and competitive field of solid tumor immunotherapy, facing rivals developing oncolytic viruses (e.g., Amgen's Imlygic, others in development), tumor-infiltrating lymphocyte (TIL) therapies, next-generation CAR-T/CAR-NK therapies for solid tumors, and bispecific antibodies. Its differentiation lies in the two-step 'tag-and-target' mechanism of the Flare platform.